SHARING IDEAS THAT DO GOOD

New therapy for those suffering Rheumatoid Arthritis

post-image
Global research-based biopharmaceutical company AbbVie has announced U.S FDA approval for their new therapy for adults with moderately to severely active rheumatoid arthritis (RA). RINVOQ is a once-daily (15mg) oral Janus kinase inhibitor supported by data from the SELECT program - one of the largest registrational Phase 3 programs in RA. Approximately 4,400 patients were evaluated across all treatment arms in five studies. The company says that RINVOQ has the potential to help additional people living with RA achieve remission who have not yet reached this goal. https://urlzs.com/SxYV2
What do you think?

You must be logged in to post a comment.
Comments
Generic placeholder image

By Mel Raassina

23 August 2019



Related Posts

Healthcare

post-image

Artificial heart to become reality with Australia-US project
18 June 2021 by Mel Raassina 0 Comments

Healthcare

post-image

The dark matter of the gut microbiome for future therapeutics
11 June 2021 by Mel Raassina 0 Comments

Healthcare

post-image

Genomic test pinpoints Covid19 risk
3 June 2021 by Marty 1 Comments